The Current Ratio as of November 2024 (TTM) for C4 Therapeutics, Inc. (CCCC) is 6.31

According to C4 Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 6.31. This represents a change of 10.59% compared to the average of 5.71 of the last 4 quarters.

C4 Therapeutics, Inc. (CCCC) Historical Current Ratio (quarterly & annually)

How has CCCC Current Ratio performed in the past?

The mean historical Current Ratio of C4 Therapeutics, Inc. over the last ten years is 5.98. The current 6.31 Current Ratio has changed 10.46% with respect to the historical average. Over the past ten years (40 quarters), CCCC's Current Ratio was at its highest in in the June 2021 quarter at 10.81. The Current Ratio was at its lowest in in the March 2019 quarter at 0.

C4 Therapeutics, Inc. (CCCC) Current Ratio by Quarter and Year

Discovering the peaks and valleys of C4 Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

C4 Therapeutics, Inc. (CCCC) Average Current Ratio

How has CCCC Current Ratio performed in the past?

The current Current Ratio of C4 Therapeutics, Inc. (CCCC) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

C4 Therapeutics, Inc. (CCCC) Current Ratio vs. Peers

How is CCCC’s Current Ratio compared to its peers?

C4 Therapeutics, Inc.’s Current Ratio is less than Shattuck Labs, Inc. (7.96), less than Eliem Therapeutics, Inc. (60.41), less than Prelude Therapeutics Incorporated (7.04), greater than Monte Rosa Therapeutics, Inc. (6.03), greater than Foghorn Therapeutics Inc. (4.77), less than Cyteir Therapeutics, Inc. (21.89), less than Rezolute, Inc. (13.79), less than Century Therapeutics, Inc. (10.39), less than Edgewise Therapeutics, Inc. (26.35), less than Mineralys Therapeutics, Inc. (8.55), less than Cullinan Oncology, Inc. (24.46), greater than Arvinas, Inc. (4.17), greater than Nurix Therapeutics, Inc. (5.28), less than Kymera Therapeutics, Inc. (8.55), less than Revolution Medicines, Inc. (14.24),

Build a custom stock screener for C4 Therapeutics, Inc. (CCCC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like C4 Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

C4 Therapeutics, Inc. (CCCC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like C4 Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.